Another recent research evaluated PD patients and unaffected controls with or without the LRRK2 G2019S mutation and evidenced a differential metabolic profile between PD and controls, highlighting lower hypoxanthine and metabolites of purine pathway (69). This evidence concerns the gene LRRK2 and Parkinson disease.